P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. (April 2023) - Bartsch, R.; Harbeck, N.; Wrobel, D.; Zaiss, M.; Terhaag, J.; Guth, D.; Distelrath, A.; Wuerstlein, R.; Zahn, M.-O.; Lüftner, D.; Schwitter, M.; Balic, M.; et al.